Abingdon Health Plc

Abingdon Health Plc

9.00
GBX
0.00
(0.00%)
2.59BMarket Cap
Mar 31Next Earn
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
- -
0.02
0.05
0.04
0.01
0.01
0.02
0.02
0.03
- -
Basic EPS, GAAP
- -
-0.01
-0.04
-0.03
-0.07
-0.01
- -
-0.01
-0.01
- -
Free Cash Flow per Basic Share
- -
-0.01
- -
-0.07
-0.03
- -
-0.01
-0.01
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.06
0.06
0.03
0.22
0.05
0.02
0.02
0.03
0.02
0.02
Tangible Book Value per Share
0.01
0.02
0.02
0.21
0.05
0.02
0.01
0.01
0.01
0.01
Basic Weighted Avg Shares
96
96
96
264
292
304
305
367
414
415
Sales/Revenue/Turnover
- -
2
5
12
3
4
6
8
11
- -
Operating Margin (%)
- -
-61.28
4.15
-46.24
-423.7
-89.27
-22.38
-41.63
-18.33
- -
Depreciation Expense
- -
- -
4
1
2
1
- -
1
1
- -
Net Income, GAAP
- -
-1
-3
-7
-21
-3
-1
-3
-2
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
-55.33
-64.45
-60.02
-749.98
-85.76
-20.72
-40.51
-19.36
- -
Working Capital
1
1
- -
12
6
3
2
2
3
3
LT Debt
- -
- -
1
1
1
1
1
1
1
1
Total Equity
6
6
3
21
6
3
2
5
6
6
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-21.18
-76.37
-57.92
-153.29
-73.93
-48.69
-90.48
-37.32
- -

Capital Structure

GBP

•

in mil. unless spec.
Jun'25
Dec'26
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
1
1
1
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
194
251
253
Market Capitalization
14
16
26

Working Capital

GBP

•

in mil. unless spec.
Jun'25
Dec'26
Jun'26
Total Current Assets
5
7
7
Cash, Cash Equivalents & STI
2
4
3
Accounts Receivable, Net
1
2
2
Inventories
1
1
1
Total Current Liabilities
3
4
4
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

GBP

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
0.58%
15.17%
Free Cash Flow
- -
-86.35%
-48.64%
Net Income, GAAP
- -
37.78%
-37.69%
Sales/Revenue/Turnover
- -
17.31%
30.42%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
6
2025
- -
- -
8
2026
- -
- -
11

Semi-annual Earnings Per Share

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
-0.01
2026
- -
- -
-0.01

Semi-annual Dividends Per Share

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

CEO
Christopher William Hand
Full Time Employees
113
Sector
Health technology
Industry
Medical specialties
Address
York Biotech Campus York YK United Kingdom YO41 1LZ
IPO Date
Dec 15, 2020
Business
Abingdon Health Plc Abingdon Health Plc (ABDX.L) develops, manufactures, and distributes lateral flow assay diagnostic tests, known as rapid tests or lateral flow immunoassays, for industries including healthcare, animal health, plant health, defence, pharmaceuticals, food, and environmental testing; offers contract development and manufacturing organization (CDMO) services encompassing full-service lateral flow assay development from proof-of-concept through scale-up, technical transfer, and routine large-scale manufacturing; provides strip and card production, device assembly, kitting, packaging, regulatory consultancy, commercial support, and analytical performance evaluation; supplies branded products such as Abingdon Simply Test self-tests, COVID-19 tests, nucleic acid lateral flow immunoassays (NALFIA) like PCRD and PCRD FLEX for detecting amplified nucleic acids via LAMP or RPA, and in-field plant health tests for pathogen detection. The company, founded in 2008 and headquartered at York Biotech Campus, Sand Hutton, York, England, with additional facilities in Doncaster, England, and Madison, Wisconsin, USA, serves global customers including wholesalers, retailers, distributors, biotech firms, and pharmaceutical companies; targets professional-use tests, self-tests, companion diagnostics, and point-of-care solutions across clinical, veterinary, agricultural, and biothreat detection segments. Recent developments include the August 2024 acquisition of regulatory service provider Compliance Solutions (Life Sciences), or CS Lifesciences, for up to £3.2 million to expand integrated CDMO capabilities; the December 2024 opening of Abingdon Analytical Ltd laboratory in Doncaster for performance evaluation services; the April 2025 launch of a US CDMO site in Madison, Wisconsin; strategic partnerships with Okos Diagnostics for avian flu (H5N1) lateral flow kits and SymbioTex for seaweed-based eco-friendly test housings; major CDMO contract wins such as a US$2 million sexually transmitted disease test project, a €2 million companion diagnostic with a European biotech, a US$2.5 million point-of-care test with a global pharmaceutical firm, a US$2 million multiplex lateral flow system, and a £800,000 UKRI-funded malaria diagnostic; and post-period fundraisings including £5.2 million in August 2024 and £3.2 million in October 2025 to support US expansion and working capital.

Company News

  • Abingdon Health Plc (ABDXF) Q4 2026 Earnings Call Transcript

  • Abingdon Health plc to Present at the Life Sciences Investor Forum on June 25th

  • Abingdon Health plc to Present at the Small Cap Growth Virtual Investor Conference June 4th

  • Abingdon Health shares to begin trading on US OTCQB market from 21 April